Adolescent obesity and related body composition, physical activity, and metabolic health outcomes Nutritional, Metabolic, Endocrine
Conditions
Interventions
This is a three-arm randomized controlled trial involving adolescents aged 12–16 years with obesity. After completion of baseline assessment, eligible participants were randomly allocated in a 1:1:1 r
Sponsors
Shandong Sport University
Eligibility
Sex/Gender
All
Age
12 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1. Adolescents aged 12–16 years 2. BMI at or above the 95th percentile for age and sex according to WHO growth reference standards 3. Had not participated in a systematic exercise program within the preceding 6 months 4. Had stable school enrollment 5. Had no diagnosed metabolic, cardiovascular, or neurological disorders 6. Provided written assent with written informed consent from a parent or legal guardian
Exclusion criteria
Exclusion criteria: 1. Currently using medications affecting metabolism or body composition, such as corticosteroids, thyroid hormones, or weight-loss pharmacotherapy 2. Diagnosed psychiatric conditions that could impair protocol adherence 3. Unable or unwilling to wear monitoring devices 4. Participating in concurrent weight-management programs 5. Metabolic, cardiovascular, or neurological disorders 6. Exercise contraindications 7. Judged during screening to have anticipated poor compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activity Fragmentation Index measured using the number of active-to-sedentary transitions per waking hour using ActiGraph GT9X accelerometer data processed with the GGIR package at baseline, week 6, week 12, and week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Moderate-to-vigorous physical activity is measured as minutes per day using ActiGraph GT9X accelerometer data processed with the GGIR package at baseline, week 6, week 12, and week 24. 2. Daily step count is measured using ActiGraph GT9X accelerometer data processed with the GGIR package at baseline, week 6, week 12, and week 24. 3. Sedentary time is measured as minutes per day using ActiGraph GT9X accelerometer data processed with the GGIR package at baseline, week 6, week 12, and week 24. 4. Body fat percentage is measured using dual-energy X-ray absorptiometry at baseline, week 12, and week 24. 5. Fat-free mass is measured using dual-energy X-ray absorptiometry at baseline, week 12, and week 24. 6. BMI percentile is calculated from measured height and body mass using WHO age- and sex-specific growth references at baseline, week 12, and week 24. 7. Waist-to-hip ratio is measured using an anthropometric tape at baseline, week 12, and week 24. 8. Resting metabolic rate is measured using indirect calorimetry with the Cosmed Quark CPET system at baseline, week 12, and week 24. 9. Respiratory exchange ratio is measured using indirect calorimetry with the Cosmed Quark CPET system at baseline, week 12, and week 24. 10. Heart rate variability, including SDNN and RMSSD, is measured using a Polar H10 heart rate monitor and Kubios HRV software at baseline, week 6, week 12, and week 24. 11. Resting heart rate is measured using a Polar H10 heart rate monitor at baseline, week 6, week 12, and week 24. 12. Fasting glucose is measured from fasting venous blood samples using the hexokinase method at baseline, week 12, and week 24. 13. Fasting insulin is measured from fasting venous blood samples using chemiluminescent immunoassay at baseline, week 12, and week 24. 14. Insulin resistance is measured using the homeostatic model assessment of insulin resistance, calculated from fasting glucose and fasting insulin, at baseline, week 12, and week 24. 15. Adiponectin is measured from | — |
Countries
China
Contacts
Public ContactGang Qin
Outcome results
None listed